ARTRYA LIMITED — Capital/Financing Update 2021

Nov 25, 2021

==> picture [576 x 15] intentionally omitted <==

==> picture [87 x 18] intentionally omitted <==

Coronary Artery Disease. We see you.

ASX ANNOUNCEMENT

26 November 2021

CARDIAC IMAGING SOFTWARE COMPANY ARTRYA LISTS ON ASX

Perth, Australia – Artificial intelligence medical technology company Artrya is pleased to announce it has been admitted to list on the Australian Securities Exchange ( ASX ) under the code AYA, following the successful completion of an initial public offer ( IPO ).

Artrya Limited ( Artrya or the Company ) will commence trading on the ASX at 12.30pm (AEDT) today, with 78,247,590 shares on issue at listing, which provides a market capitalisation of the Company of $105.6 million at the IPO price of $1.35. The IPO was well supported by a range of existing and new investors raising a total of $40 million.

Artrya Managing Director and Co-founder, John Barrington AM, said it was an important day for Artrya listing on the ASX, and the support from investors during the IPO was encouraging.

“Nine million individuals die from coronary artery disease each year globally and this number is expected to increase over the next few decades, as ageing populations continue to put pressure on health systems.

“This float will assist the Company in pursuing further growth in the US, UK, Canada, and Europe. We are keenly focused on product development and market entry strategies to ensure our shareholders are rewarded for their belief in an innovative Australian business,” said Mr Barrington.

As disclosed in Artrya’s prospectus dated 15 October 2021 as supplemented by the supplementary prospectus dated 10 November 2021, Artrya has recently been appointed to the United Kingdom National Health Service Shared Business Services (NHS SBS) Framework as a supplier of artificial intelligence software and platforms, following a successful tender bid.

Under the NHS SBS framework agreement Artrya is listed among a select, preferred, and pre-qualified shortlist of approved suppliers from which various public organisations, including 1,250 NHS hospitals, can commission services.

Artrya’s core solution is the novel technology Salix – a fast and effective AI-based solution which analyses cardiac CT scans to detect a unique combination of heart attack biomarkers. Salix supports clinicians in the early diagnosis of coronary artery disease by highlighting disease location and severity on a 3D heart image and producing a comprehensive patient report in approximately 15 minutes, assisting first-time-right treatment.

Market pilots of Artrya’s Salix Coronary Anatomy (SCA) product are presently underway in Australia and it is expected a number of the pilot programs will progress to commercial use in the first half 2022.

This announcement was approved by the Company’s Managing Director, John Barrington AM, on behalf of the Artrya Board.

For further information please contact:

Investor Enquiries: Media Enquiries: John Barrington Felicity Heath Artrya Limited Daymark 0419 850 502 0457 196 603 investors@artrya.com felicity.heath@daymark.com.au

Artrya Limited ABN 53 624 005 741 Suite 14A Level 3 88 Broadway Crawley WA 6009 Australia www.artrya.com